FDA Modernization Act 3.0
HB2821, titled the FDA Modernization Act 3.0, directs the Secretary of Health and Human Services, through the FDA Commissioner, to issue an interim final rule within one year to update FDA regulations to use the term “nonclinical” instead of “animal” in specified regulatory provisions. The bill is designed to conform FDA regulations to changes made in the Consolidated Appropriations Act, 2023, which amended the Federal Food, Drug, and Cosmetic Act to recognize nonclinical testing methods. It also requires the FDA to add the statutory definition of “nonclinical test” into several parts of title 21 of the Code of Federal Regulations and to make any other conforming regulatory changes needed for consistency.
In addition to the regulatory language update, the bill includes a technical amendment to the Federal Food, Drug, and Cosmetic Act to renumber an existing subsection related to clinical trial diversity action plans. The bill specifies that the interim final rule becomes effective immediately, without the usual need for the agency to show good cause for bypassing standard notice-and-comment timing. Overall, the measure is aimed at accelerating FDA implementation of nonclinical testing reforms and ensuring the agency’s regulations match current statutory language.
The bill would affect FDA regulations under the Federal Food, Drug, and Cosmetic Act, especially provisions governing investigational new drugs, drug applications, biologics, and related nonclinical testing requirements in title 21 of the Code of Federal Regulations. It would not itself create a new testing regime, but it would require the agency to revise regulatory text, replace outdated references to animal testing with nonclinical testing terminology, and incorporate the statutory definition across multiple regulatory sections. The practical effect would be to speed regulatory alignment with existing law and potentially influence how sponsors, researchers, and FDA reviewers describe and submit preclinical evidence.
The bill appears generally supportive of FDA modernization and nonclinical testing reform, with bipartisan sponsorship suggesting broad interest in updating regulatory language and implementation. The available record shows no committee transcript, recorded vote, or formal opposition in the provided materials, so there is no documented floor or committee controversy in this dataset. The overall tone of the measure is administrative and implementation-focused rather than ideological, emphasizing conformity, clarity, and prompt agency action.
The main potential point of contention is the bill’s directive that FDA issue an interim final rule that becomes effective immediately, which reduces the usual opportunity for prior public comment and may be viewed as limiting procedural input. Another possible area of debate is the broader policy shift away from references to animal testing toward nonclinical methods, which could draw scrutiny from stakeholders concerned about regulatory flexibility, scientific standards, or the pace of implementation. However, no specific objections, amendments, or recorded opposition are included in the provided materials.